Emergency Contraceptive's Length Of Efficacy Likely Focus Of FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The Reproductive Health Drugs Advisory Committee will consider the the five-day claim sought by HRA Pharma's Ella (ulipristal acetate) which would give it a two-day advantage over Teva's Plan B (levonorgestrel) in preventing pregnancy after unprotected intercourse.